Acute and inflammatory in vivo pain models
Supported by:
22 February 2017
Despite its ubiquity, pain is a largely unmet clinical need. Poor response rates and/or strong adverse reactions to currently available medications highlight the need for new, effective treatment compounds. The best way to accomplish this is through developing validated animal models for research.
This webinar discusses our newly validated acute and inflammatory in vivo pain models, including information on how they were validated and how they can be used to test new pain treatment compounds, eventually leading to clinical translation.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Assays, Drug Discovery Processes, In Vivo
Related organisations
Charles River Laboratories
